Nalaganje...
The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis
INTRODUCTION: Lumacaftor-ivacaftor is indicated for treatment of cystic fibrosis (CF) in patients homozygous for the Phe-508del cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations. In clinical trials, treated patients showed improved pulmonary function, reduced pulmonary exacer...
Shranjeno v:
| izdano v: | Expert Opin Drug Saf |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2017
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209511/ https://ncbi.nlm.nih.gov/pubmed/28846049 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14740338.2017.1372419 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|